HCV in the Australian primary care setting: real-world effectiveness of 12 weeks of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C

被引：0
|
作者：
O'Loan, Joss [1 ,2 ]
Balcomb, Anne [3 ]
Baker, David [4 ]
Doyle, Joseph [5 ,6 ]
Godfrey, Daniel [7 ]
Kozminsky, Michael [8 ]
Mertens, Michael [9 ]
Vanstraelen, Kim [9 ]
Young, Matt [1 ,2 ]
机构：
[1] Med Clin, Inala, Australia
[2] Kombi Clin, Brisbane, Qld, Australia
[3] Prince St Clin, Orange, NSW, Australia
[4] East Sydney Doctors, Darlinghurst, NSW, Australia
[5] Alfred, Melbourne, Vic, Australia
[6] Monash Univ, Dept Infect Dis, Melbourne, Vic, Australia
[7] Gilead Sci Pty Ltd, Melbourne, Vic, Australia
[8] Genesis Med Ctr, Brighton, Australia
[9] Gilead Sci Ltd, London, England
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU419
引用
收藏
页码：S346 / S346
页数：1
相关论文
共 50 条
  • [21] Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China
    Yunjing Zhou
    Minfeng Liang
    Yiting Li
    Xing Chen
    Jie Yang
    Honglian Bai
    Yingzi Long
    Xiaohong Zhang
    Chaoshuang Lin
    BMC Gastroenterology, 24
  • [22] Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort
    Wong, Yu Jun
    Thurairajah, Prem Harichander
    Kumar, Rahul
    Tan, Jessica
    Fock, Kwong Ming
    Law, Ngai Moh
    Li, Weiquan
    Kwek, Andrew
    Tan, Yu Bin
    Koh, Jingyun
    Lee, Zheng Cong
    Kumar, Loshini Senthil
    Teo, Eng Kiong
    Ang, Tiing-Leong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (05) : 1300 - 1308
  • [23] Real-World Safety and Effectiveness of Sofosbuvir/Velpatasvir/Voxilaprevir and Glecaprevir/Pibrentasvir in Hepatitis C Infected Patients
    Saxena, Varun
    Chamberland, Scott
    Hurley, Leo
    Lai, Jennifer B.
    Truong, Elizabeth
    Marcus, Julia
    Champsi, Jamila
    Hare, Brad B.
    Korn, Daniel
    Ready, Joanna B.
    Seo, Suk
    Witt, David J.
    Silverberg, Michael J.
    HEPATOLOGY, 2018, 68 : 418A - 419A
  • [24] Sofosbuvir and velpatasvir in the treatment of chronic hepatitis C
    Wuerth, Kelli
    Magel, Tianna
    Conway, Brian
    FUTURE VIROLOGY, 2019, 14 (11) : 715 - 727
  • [25] Real-world effectiveness and cost per SVR of ledipasvir/sofosbuvir chronic hepatitis C treatment
    Buggisch, Peter
    Wursthorn, Karsten
    Stoehr, Albrecht
    Gauthier, Aline
    Atanasov, Petar K.
    Petersen, Joerg
    HEPATOLOGY, 2015, 62 : 791A - 791A
  • [26] Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C
    Buggisch, Peter
    Vermehren, Johannes
    Mauss, Stefan
    Guenther, Rainer
    Schott, Eckart
    Pathil, Anita
    Boeker, Klaus
    Zimmermann, Tim
    Teuber, Gerlinde
    Vornkahl, Heike-Pfeiffer
    Simon, Karl-Georg
    Niederau, Claus
    Wedemeyer, Heiner
    Zeuzem, Stefan
    JOURNAL OF HEPATOLOGY, 2018, 68 (04) : 663 - 671
  • [27] Effectiveness of ledipasvir/sofosbuvir in real-world patients with chronic hepatitis C: a collaborative treatment approach
    Johnson, Steven W.
    Ammirati, Shelby R.
    Hartis, Charles E.
    Weber, Stephen F.
    Morgan, Michael R.
    Darnell, Timothy A.
    Silwal, Adwait
    Schmidlin, Holly N.
    Priest, David H.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 49 (06) : 778 - 781
  • [28] EFFICACY AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA
    Yue, Wei
    Liu, Li
    Xiao, An
    Du, Yingrong
    Gao, Jianpeng
    Liu, Min
    Wang, Yilan
    Che, Meng
    Guo, Jiaxiang
    Li, Junyi
    Geng, Jiawei
    HEPATOLOGY, 2021, 74 : 589A - 589A
  • [29] Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study
    Tapper, E. B.
    Bacon, B. R.
    Curry, M. P.
    Dieterich, D. T.
    Flamm, S. L.
    Guest, L. E.
    Kowdley, K. V.
    Lee, Y.
    Tsai, N. C.
    Younossi, Z. M.
    Afdhal, N. H.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (01) : 22 - 27
  • [30] Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
    Pin-Nan Cheng
    Lein-Ray Mo
    Chun-Ting Chen
    Chi-Yi Chen
    Chung-Feng Huang
    Hsing-Tao Kuo
    Ching-Chu Lo
    Kuo-Chih Tseng
    Yi-Hsiang Huang
    Chi-Ming Tai
    Cheng-Yuan Peng
    Ming-Jong Bair
    Chien-Hung Chen
    Ming-Lun Yeh
    Chih-Lang Lin
    Chun-Yen Lin
    Pei-Lun Lee
    Lee-Won Chong
    Chao-Hung Hung
    Te Sheng Chang
    Jee-Fu Huang
    Chi-Chieh Yang
    Jui-Ting Hu
    Chih-Wen Lin
    Chia-Chi Wang
    Wei-Wen Su
    Tsai-Yuan Hsieh
    Chih-Lin Lin
    Wei-Lun Tsai
    Tzong-Hsi Lee
    Guei-Ying Chen
    Szu-Jen Wang
    Chun-Chao Chang
    Sheng-Shun Yang
    Wen-Chih Wu
    Chia-Sheng Huang
    Kwok-Hsiung Chou
    Chien-Neng Kao
    Pei-Chien Tsai
    Chen-Hua Liu
    Mei-Hsuan Lee
    Chien-Yu Cheng
    Ming-Chang Tsai
    Chun-Jen Liu
    Chia-Yen Dai
    Han-Chieh Lin
    Jia-Horng Kao
    Wan-Long Chuang
    Ming-Lung Yu
    Infectious Diseases and Therapy, 2022, 11 : 485 - 500
12345